BioCryst Pharmaceuticals (NASDAQ:BCRX) reported third-quarter results marked by growth in ORLADEYO revenue, higher profitability and progress across its hereditary angioedema, or HAE, portfolio, while maintaining its full-year ORLADEYO revenue outlook following a specialty-pharmacy transition.
ORLADEYO net revenue was $174.8 million in the quarter, with more than 95% generated in the U.S., Chief Financial Officer Babar Ghias said. Excluding European revenue, ORLADEYO revenue increased 20% year over year on a comparable basis.
The quarter’s revenue included an upper-teens-million-dollar contribution from inventory built by CareMed, BioCryst’s new sole-source pharmacy partner for ORLADEYO shipments. Ghias said CareMed typically carries seven to 21 days of inventory and built inventory at the lower end of that range during the quarter. He characterized the contribution as a one-time benefit of that magnitude, saying future revenue should more closely track underlying patient demand.
CareMed Transition and Pediatric Launch
President and CEO Charlie Gayer said BioCryst moved to CareMed because ORLADEYO’s patient volume had reached a scale at which pharmacy operations could materially affect patient growth and shipments of paid product. The company said early results from the partnership included improved time to first shipment for new patients, although management noted the transition was still in its early stages.
BioCryst launched ORLADEYO pellets for children ages 2 to 11 in August. Gayer said children across the full approved age range have started treatment and that the mix includes patients switching from other prophylactic therapies, patients previously using acute treatments only, and treatment-naive patients.
The company plans to launch its recently approved 150-milligram ORLADEYO pellet formulation for patients ages 12 and older at the American College of Allergy, Asthma, and Immunology meeting. Gayer said the formulation could serve adolescents and adults who have difficulty swallowing capsules or prefer pellets.
While BioCryst did not disclose quarterly pediatric prescription figures, Gayer said uptake remained ahead of internal expectations. He said pediatric revenue will represent only a small portion of 2026 revenue, but the early launch performance suggests the pediatric market could exceed the company’s previously cited estimate of 500 diagnosed and treated patients.
Management said ORLADEYO’s paid prescription rate ended the quarter at approximately 82% to 83%. Gayer said the company believes CareMed’s capabilities could help it meet or potentially exceed its long-term steady-state goal of an 85% paid rate.
Profitability and Updated Revenue Outlook
BioCryst reported non-GAAP operating profit of $86 million, up 70% from the prior-year quarter, and non-GAAP net income of $71 million, more than double the year-earlier period. Cash and equivalents totaled $376 million at quarter-end.
Ghias said the company recorded approximately $19 million in restructuring-related expenses during the quarter, including about $10 million of cash costs. The expenses were primarily tied to the closure of BioCryst’s Birmingham facility and associated organizational restructuring. The company expects the actions to generate $30 million to $35 million in annualized savings once fully realized, with restructuring activities substantially completed by year-end.
The company tightened its full-year 2026 operating expense guidance to $415 million to $425 million. Ghias said BioCryst expects operating expenses to decline further in 2027 as the benefits of its cost actions are fully realized.
BioCryst maintained its 2026 ORLADEYO revenue guidance of $625 million to $645 million, despite the CareMed inventory contribution. Management said it did not want to alter guidance based on a one-time inventory dynamic while the transition remains underway.
The company raised total revenue guidance to $715 million to $730 million, reflecting higher realized licensing revenue and international RAPIVAB orders from a partner. Ghias said RAPIVAB is not a strategic core asset and is largely a low-margin pass-through business.
Pipeline Progress and HAE Strategy
BioCryst said its pivotal navenibart trial was fully enrolled in June and remains on track to report top-line data through 12 months of therapy in the third quarter of 2027. The company is preparing its biologics license application and commercial launch plans for the potential HAE treatment.
Gayer said the company’s long-term HAE opportunity depends on continued ORLADEYO growth and a strong navenibart launch. He said market research indicates navenibart’s potential three- and six-month dosing intervals, combined with efficacy and convenient administration, could encourage patients using other injectable prophylactic therapies to switch.
Regarding future oral competition, Gayer said BioCryst’s annual market research modeled deucrictibant with a profile slightly stronger than the results ultimately reported in its Phase 3 trial. The company’s model indicated that the competing product could gain market share but would not take away ORLADEYO’s existing patient base, he said.
BioCryst also completed enrollment in part four of its BCX17725 study in Netherton syndrome and expects early clinical data by year-end. Chief R&D Officer Sandeep Menon said the company plans to report the primary endpoint, key secondary endpoints, safety and tolerability. He said a 20% to 25% improvement in the Ichthyosis Area and Severity Index, or IASI, score would be considered clinically meaningful based on the company’s research and discussions with key opinion leaders, though regulatory discussions are still pending.
Menon said BioCryst would evaluate the full data package before determining next steps and would not automatically move directly into a pivotal trial. The company is taking what Ghias described as an evidence-based approach to investment, seeking clinical data before committing spending to later-stage development activities.
External Innovation Focus
BioCryst also highlighted its strategic shift toward building its pipeline through external innovation. Menon said the company’s newly formed scientific advisory board is actively reviewing potential opportunities, primarily early clinical-stage assets in Phase 1 or Phase 2 with clear biological rationale.
Management said it intends to focus on programs that fit its commercial capabilities in rare diseases rather than expanding the pipeline solely for size. Gayer said BioCryst has assembled internal scientific evaluation and business-development teams, with the advisory board helping assess opportunities the company identifies.
About BioCryst Pharmaceuticals (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.
BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.
Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.
